A new pilot program tests anonymous, pseudonymous daily check-ins for AA and NA sponsors to support multiple sponsees while maintaining anonymity.
Anonymous daily check-ins for 12-step sponsors
Browsing Category
Healthcare operations
42 posts
Consumer Health Innovation: CRISPR’s Selective Attack On Difficult Cancer Cells
Recent research shows CRISPR selectively destroys hard-to-treat cancer cells, including ‚undruggable‘ types, offering potential for consumer health applications.
Hone Health And WTHN Announce Longevity Partnership
Hone Health and WTHN announce a new partnership focused on advancing longevity and wellness initiatives, combining their expertise to develop innovative health solutions.
TransMedics To Report Second Quarter 2026 Financial Results On August 4, 2026
TransMedics will release its second quarter 2026 financial results on August 4, 2026, providing insights into its recent performance and outlook.
Neuronata-R Retains Conditional Approval In South Korea
Neuronata-R retains its conditional approval status in South Korea, with ongoing review processes. The decision impacts future use and development of the drug.
Daily Home Visits To Support Postpartum Maternal Health
A new pilot tests daily postpartum check-ins for first-time mothers discharged early, aiming to improve recovery and reduce risks in the critical first two weeks.
4DMT Announces Positive 2-Year Data From PRISM Phase 2B Clinical Trial In A Broad Wet AMD Population
4DMT announces favorable 2-year data from its PRISM Phase 2b clinical trial targeting wet AMD, showing promising efficacy and safety outcomes.
Orthopedic Surgery Recovery: The Importance Of Percentile Monitoring
A new recovery-percentile tracker for post-op orthopedic patients is being tested to reduce patient calls and improve care. Results expected soon.
Novartis Fabhalta® (Iptacopan) Receives FDA Traditional Approval As First And Only Complement Inhibitor To Significantly Slow Kidney Function Decline In Primary IgAN
Novartis‘ Fabhalta® (iptacopan) receives FDA traditional approval as the first complement inhibitor proven to slow kidney decline in IgA nephropathy.
Lynk Pharmaceuticals Announces Completion Of Patient Enrollment In Phase III Clinical Trial Of Zemprocitinib For Ankylosing Spondylitis
Lynk Pharmaceuticals has finished enrolling patients in its Phase III clinical trial for Zemprocitinib targeting ankylosing spondylitis, marking a key milestone.
